GRIFOLS S A/S (GRFS) Downgraded to “Sell” at BidaskClub

BidaskClub cut shares of GRIFOLS S A/S (NASDAQ:GRFS) from a hold rating to a sell rating in a report published on Tuesday morning.

Other equities research analysts have also issued research reports about the stock. Berenberg Bank upgraded shares of GRIFOLS S A/S from a hold rating to a buy rating in a report on Thursday, October 11th. Zacks Investment Research upgraded shares of GRIFOLS S A/S from a sell rating to a hold rating in a report on Tuesday, November 13th. Santander upgraded shares of GRIFOLS S A/S from an underperform rating to a hold rating in a research note on Tuesday, October 30th. UBS Group lowered shares of GRIFOLS S A/S from a neutral rating to a sell rating in a research note on Wednesday, October 3rd. Finally, Morgan Stanley reduced their price objective on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an underweight rating for the company in a research note on Monday, October 1st. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $21.50.

NASDAQ:GRFS opened at $19.26 on Tuesday. GRIFOLS S A/S has a one year low of $17.47 and a one year high of $25.18. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.78 and a quick ratio of 1.07. The stock has a market capitalization of $13.20 billion, a PE ratio of 17.51, a price-to-earnings-growth ratio of 1.39 and a beta of 1.12.

The company also recently disclosed a special dividend, which will be paid on Tuesday, December 11th. Investors of record on Monday, December 3rd will be paid a dividend of $0.2283 per share. This represents a dividend yield of 2.25%. The ex-dividend date is Friday, November 30th. This is a positive change from GRIFOLS S A/S’s previous special dividend of $0.01. GRIFOLS S A/S’s payout ratio is 31.82%.

Several hedge funds and other institutional investors have recently bought and sold shares of GRFS. Jefferies Group LLC bought a new position in shares of GRIFOLS S A/S during the 3rd quarter worth approximately $333,000. Opus Point Partners Management LLC raised its stake in shares of GRIFOLS S A/S by 32.2% during the 3rd quarter. Opus Point Partners Management LLC now owns 16,445 shares of the biotechnology company’s stock worth $351,000 after acquiring an additional 4,003 shares in the last quarter. Verition Fund Management LLC raised its stake in shares of GRIFOLS S A/S by 23.2% during the 2nd quarter. Verition Fund Management LLC now owns 18,818 shares of the biotechnology company’s stock worth $405,000 after acquiring an additional 3,539 shares in the last quarter. AMP Capital Investors Ltd bought a new position in shares of GRIFOLS S A/S during the 2nd quarter worth approximately $438,000. Finally, Janney Montgomery Scott LLC bought a new position in shares of GRIFOLS S A/S during the 3rd quarter worth approximately $438,000. Hedge funds and other institutional investors own 20.17% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Featured Article: Cost of Equity

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply